# Multicentric, randomized, comparative, openlabeled trial of a fixed dose combination of cefepime and amikacin versus cefepime alone in nosocomial pneumonia

Submission date	<b>Recruitment status</b> No longer recruiting	Prospectively registered		
06/06/2006		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
23/06/2006	Completed	[X] Results		
<b>Last Edited</b>	Condition category	[] Individual participant data		

#### Plain English summary of protocol

Not provided at time of registration

### Contact information

## Type(s)

Scientific

#### Contact name

Prof K.C Mohanty

#### **Contact details**

Professor and Head K.J.Somaiya Medical Hospital and Research Centre Department of Chest Medicine Mumbai India 400022

## Additional identifiers

**EudraCT/CTIS** number

**IRAS** number

ClinicalTrials.gov number

Secondary identifying numbers

## Study information

#### Scientific Title

Multicentric, randomized, comparative, open-labeled trial of a fixed dose combination of cefepime and amikacin versus cefepime alone in nosocomial pneumonia

#### Acronym

**RCCT** 

#### **Study objectives**

The objective of the trial was to compare the efficacy and safety of cefepime and amikacin fixed dose combination with cefepime alone in patients with nosocomial pneumonia.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Approval given by Institutional Ethics Committee, reference number: Ct/ca/01

#### Study design

Open-labeled, randomized controlled clinical trial

#### Primary study design

Interventional

#### Secondary study design

Randomised controlled trial

#### Study setting(s)

Not specified

#### Study type(s)

Treatment

#### Participant information sheet

#### Health condition(s) or problem(s) studied

Nosocomial pneumonia

#### **Interventions**

100 Patients were treated with cefepime and amikacin fixed-dose combination (FDC) 2.5 g twice a day (bid) and 100 patients received cefepime 2 g bid for 7-10 days

#### Intervention Type

Drug

#### Phase

**Not Specified** 

#### Drug/device/biological/vaccine name(s)

cefepime, amikacin

#### Primary outcome measure

Outcome of therapy was based on clinical evaluation and bacteriological evaluation. Bacteriological evaluation was in terms of presence or absence of bacteria in sputum.

#### Secondary outcome measures

The cure rate was 65% in the cefepime and amikacin FDC group while clinical improvement was noticed in 24% of the patients. In the group treated with cefepime alone, the cure rate was 44%, while 27% showed clinical improvement. Mild adverse reactions were noticed in both groups.

#### Overall study start date

01/11/2005

#### Completion date

31/03/2006

## **Eligibility**

#### Key inclusion criteria

Participants included were 200 patients infected with nosocomial pneumonia showing presence of pus cells more than 25 high power fields (HPF) and buccal epithelial cells less than 10 HPF

#### Participant type(s)

**Patient** 

#### Age group

Adult

#### Sex

Both

#### Target number of participants

200

#### Total final enrolment

200

#### Key exclusion criteria

- 1. Hypersensitivity to cefepime, amikacin or related drugs
- 2. Children or adolescents less than 18 years of age
- 3. Pregnant women
- 4. Patients with renal or hepatic insufficiency
- 5. Patients not willing to give written informed consent

#### Date of first enrolment

01/11/2005

#### Date of final enrolment

## Locations

### Countries of recruitment

India

## Study participating centre Professor and Head

Mumbai India 400022

## Sponsor information

#### Organisation

Venus Remedies Limited (India)

#### Sponsor details

Intellectual Scientific Division
Research and Development Centre
51-52 Industrial Area
Phase-1
Panchkula
Haryana
India
134113
+91 17 22561244
operations@venusremedies.com

#### Sponsor type

Industry

#### Website

http://www.venusremedies.com

#### **ROR**

https://ror.org/0169rv113

## Funder(s)

## Funder type

Industry

#### Funder Name

Venus Remedies Limited

## **Results and Publications**

## Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/05/2008	08/01/2021	Yes	No